40 completed. 40 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 40 | Completed 40 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow Overactive Bladder: new trials by email Literature Review of Overactive Bladder trials Research Report on Overactive Bladder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Extended Release Torsemide in Patients With Congestive Heart Failure and Overactive Bladder Extended release torsemide, Immediate release torsemide, Extended release torsemide placebo - Heart Failure, Overactive Bladder | Phase 2 | Completed | Sarfez Pharmaceuticals, Inc. | 24 | 2024-06-15 | 2026-03-12 |
| Lidocaine Patches Prior to Percutaneous Nerve Evaluation Lidocaine patch, Placebo - Overactive Bladder, Urge Incontinence | Phase 2 | Completed | University of Louisville | 39 | 2023-05-01 | 2025-02-03 |
| Urinary Microbiome Changes Following Administration of 500 mg of NDS-446 in Women With Dry OAB at 12 Weeks 500 mg NDS-446 - Overactive Bladder | Phase 2 | Completed | Loyola University | 53 | 2023-01-01 | 2026-06-17 |
| Clinical Study to Evaluate the Treatment Effect and Safety of BAY1817080 in Patients With Overactive Bladder (OAB) Placebo, BAY1817080 - Overactive Bladder | Phase 2 | Completed | Bayer | 99 | 2020-09-16 | 2022-12-22 |
| A Therapeutic Exploratory Clinical Study of DA-8010 in Patients With Overactive Bladder DA-8010 Placebo, DA-8010 2.5mg, DA-8010 5mg - Overactive Bladder | Phase 2 | Completed | Dong-A ST Co., Ltd. | 306 | 2018-07-10 | 2020-02-07 |
| A Study to Evaluate Once Daily Low Dose and High Dose Solabegron or Placebo Given for 12 Weeks to Treat Women With Symptoms of Overactive Bladder: Sudden Urge to Urinate, Frequent Urination Associated With Wetting Episodes (VEL-2001) Solabegron modified release tablets, low dose, Solabegron modified release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 1413 | 2018-07-09 | 2020-03-02 |
| Evaluation of the Efficacy and Safety of Solabegron Tablets for Treatment of Overactive Bladder in Adult Women Solabegron immediate release tablets, low dose, Solabegron immediate release tablets, high dose, Matching Placebo - Overactive Bladder | Phase 2 | Completed | Velicept Therapeutics, Inc. | 438 | 2018-02-19 | 2020-03-02 |
| Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. TAC-302, Placebo - Detrusor Underactivity, Overactive Bladder | Phase 2 | Completed | Taiho Pharmaceutical Co., Ltd. | 195 | 2017-09-09 | 2025-01-20 |
| Mirabegron For Erectile Dysfunction Mirabegron - Erectile Dysfunction, Overactive Bladder | Phase 1 / Phase 2 | Completed | Johns Hopkins University | 20 | 2017-08-01 | 2021-01-05 |
| Study of ONO-8577 in Patients With Overactive Bladder ONO-8577, solifenacin succinate + mirabegron, Placebo - Overactive Bladder | Phase 2 | Completed | Ono Pharmaceutical Co., Ltd. | 207 | 2017-04-07 | 2024-05-03 |
| A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment fesoterodine 4mg, Oxybutynin, placebo - Overactive Bladder, Mild Cognitive Impairment | Phase 2 | Completed | University of Alberta | 47 | 2016-08-01 | 2020-02-19 |
| Instillation of Botox in the Bladder in Women With Overactive Bladder (OAB) onabotulinum toxin A - Overactive Bladder | Phase 2 | Completed | The Hospital of Vestfold | 14 | 2016-03-01 | 2018-11-26 |
| Study Evaluating the Safety, Tolerability, and Efficacy of Dexmecamylamine (TC-5214) for Treatment of Overactive Bladder dexmecamylamine, Placebo - Overactive Bladder | Phase 2 | Completed | Targacept Inc. | 1635 | 2013-05-01 | 2015-06-03 |
| Transcutaneous Tibial Nerve Stimulation of Patients With Overactive Bladder (OAB) Syndrome The Geko - Overactive Bladder, Multiple Sclerosis | Phase 2 | Completed | University College, London | 48 | 2013-01-01 | 2016-06-03 |
| Interventional Clinical Trial in Patients in Overactive Bladder With Nocturia in Women Tolterodine tartrate extended release capsules, Desmopressin orally disintegrating tablets, Placebo orally disintegrating tablets - Overactive Bladder | Phase 2 | Completed | Ferring Pharmaceuticals | 106 | 2013-01-01 | 2018-09-12 |
| Different Injection Number of the Same Dose of Botulinum Toxin A on Overactive Bladder Syndrome BoNT-A (10 injection), BoNT-A (20 injection), BoNT-A (40 injection) - Overactive Bladder | Phase 2 | Completed | Buddhist Tzu Chi General Hospital | 90 | 2012-08-01 | 2017-02-15 |
| Bacterial Genomic Sequencing in Overactive Bladder Solifenacin - Overactive Bladder | Phase 2 | Completed | Loyola University | 134 | 2012-07-01 | 2015-12-07 |
| A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. Tarafenacin 0.2 mg, Placebo, Tarafenacin 0.4 mg - Overactive Bladder | Phase 2 | Completed | Kwang Dong Pharmaceutical co., ltd. | 235 | 2011-09-01 | 2014-03-12 |
| Bryophyllum Versus Placebo for Overactive Bladder Bryophyllum pinnatum, Placebo in form of Lactose - Overactive Bladder | Phase 2 | Completed | University of Zurich | 22 | 2010-12-01 | 2012-01-19 |
| Study of AOBO-001 for Overactive Bladder With Urge Urinary Incontinence and Frequency AOBO-001, Placebo - Overactive Bladder | Phase 2 | Completed | American Oriental Bioengineering, Inc. | 66 | 2010-12-01 | 2013-01-23 |
Showing 20 of 40. Sign in to see all of them.
Urinary Bladder, Overactive (40) · Urinary Incontinence (9) · Urinary Incontinence, Urge (4) · Lower Urinary Tract Symptoms (2) · Cognitive Dysfunction (1) · Erectile Dysfunction (1) · Fecal Incontinence (1) · Heart Failure (1) · Male Urogenital Diseases (1) · Multiple Sclerosis (1) · Urinary Bladder, Underactive (1) · Urinary Tract Infections (1)
Female Urogenital Diseases (40) · Female Urogenital Diseases and Pregnancy Complications (40) · Pathological Conditions, Signs and Symptoms (40) · Signs and Symptoms (40) · Urinary Bladder Diseases (40) · Urogenital Diseases (40) · Urologic Diseases (40) · Urological Manifestations (40) · Male Urogenital Diseases (39) · Lower Urinary Tract Symptoms (38) · Urination Disorders (12) · Urinary Incontinence (3) · Mental Disorders (2) · Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1)
Tolterodine Tartrate (6) · Botulinum Toxins, Type A (5) · Solifenacin Succinate (3) · fesoterodine (3) · incobotulinumtoxinA (2) · mirabegron (2) · solabegron (2) · DA-8010 (1) · Dimethyl Sulfoxide (1) · Drug Therapy (1) · ONO-8539 (1) · Pregabalin (1) · Tamsulosin (1) · Vardenafil Dihydrochloride (1) · abobotulinumtoxinA (1)
Pfizer (4) · Ono Pharmaceutical Co., Ltd. (3) · Bayer (2) · Buddhist Tzu Chi General Hospital (2) · GlaxoSmithKline (2) · Loyola University (2) · Sanofi (2) · Velicept Therapeutics, Inc. (2) · APOGEPHA Arzneimittel GmbH (1) · Allergan (1) · American Oriental Bioengineering, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Astellas Pharma Inc (1) · Dong-A ST Co., Ltd. (1) · Ferring Pharmaceuticals (1)
United States (18) · Germany (7) · Czechia (6) · Poland (6) · Canada (5) · France (5) · Netherlands (5) · South Korea (4) · Sweden (4) · Taiwan (4) · United Kingdom (4) · Belgium (3) · Hungary (3) · Japan (3) · Norway (3)
Hann-Chorng Kuo, M.D. (2) · Adrian S Wagg, MD (1) · Alan J Wolffe, PhD (1) · Alvin Chandra, MD (1) · Arthur L Burnett, M.D., M.B.A. (1) · Brooke Derby (1) · Elizabeth Mueller, MD (1)
PMID 26423260, PMID 12559262, PMID 12811491, PMID 16460875, PMID 17049716, PMID 18584946, PMID 19648387, PMID 19941278, PMID 20384395, PMID 20639026, PMID 20804630, PMID 22036776, PMID 22047020, PMID 22174279, PMID 22258963, PMID 22278835, PMID 22464310, PMID 22748867, PMID 23076891, PMID 23218404, PMID 23741373, PMID 24371246, PMID 24515544, PMID 25006228, PMID 25623739, PMID 26049866, PMID 26210757, PMID 26824901, PMID 26962083, PMID 27214047, PMID 28196724, PMID 28486927, PMID 31233095, PMID 31930360, PMID 32317321, PMID 32791124, PMID 32945735, PMID 34036621, PMID 34978027, PMID 36205739, PMID 36892754, PMID 37160401, PMID 37811598, PMID 38402104, PMID 40013530
2019 (1)